In Birmingham, England last week, THE DARK REPORT and the United Kingdom’s Association of Clinical Biochemists (ACB) conducted the fourth annual “Frontiers in Laboratory Medicine” (FiLM) meeting, which showcases laboratory best practices in North America and the United Kingdom. At FiLM, it was suggested that lab directors and pathologists in the United States and Canada may be interested in attending next year’s event and visiting several laboratories in England. Should any clients or readers be interested in traveling next February to England for FiLM and laboratory site visits, they should contact Robert Michel at firstname.lastname@example.org. He will gauge interest and work to arrange such a tour.
XIFIN ADDS DIRECTOR
XIFIN, Inc. has added Judd Jessup to its board of directors. Jessup was CEO of US LABS, Inc. and helped sell it to Laboratory Corporation of America in early 2005. Located in San Diego, California, XIFIN offers laboratories an ASP-based system for accounts receivable and financial management.
EARLY-STAGE TEST FOR LUNG CANCER SHOWS PROMISE
Efforts to develop a blood test that can detect non-small cell lung cancer (NSCLC) in early stages is showing promise. In a few months, researchers at the University of Kentucky (UK) expect to present new data on this lab test to the National Cancer Institute (NCI) Early Detection Re- search Network. Edward Hirschowitz, M.D., Li Zhong, Ph.D., and their colleagues identified antibodies produced in response to lung cancer development. Studies con- ducted to date indicate a 90% ability to predict NSCLC, even in its earliest stages.
ADD TO: Lung Cancer Test
Market potential for this test is significant. About 172,000 new cases of lung cancer are diagnosed each year. Since most diagnoses are made later in the course of disease, lung cancer deaths total approximately 160,000 annually. Because NSCLC is involved in 80% of lung cancer cases, there would be strong interest in a highly-sensitive blood test that can detect NSCLC in its early stages. In December, the University of Kentucky licensed exclusive rights to this test to 20/20 GeneSystems, Inc., a firm in Rockville, Maryland. The company says it will use its proprietary layered peptide array (LPA) platform and the UK team’s biomarkers to create a screening test for the early detection of lung cancer.
OMLON THE MOVE
Oregon Medical Laboratories, Inc. (OML) is on the move—literally! Last month it moved into spacious new quarters, following a one-year build-out of a 70,000 square-foot lab facility. The new lab is located in Springfield, Oregon, a bedroom community for nearby Eugene. OML has installed an automated specimen processing system manufactured by Probenver-teiltechnik GmbH (PVK). It is the first lab in the United States to install one of PVK’s automated systems.